SGLT2 inhibitors and risk of genitourinary infections

Chaplin, Steve

doi:10.1002/psb.1521

Cited by 17 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies report that SGLT2i has some adverse effects and that these drugs are associated with hypotension, dehydration, urinary tract infections, diabetic ketoacidosis, fragility fractures, and risk of lower-limb amputations [25,34,35]. It is recommended not to prescribe these medications in the elderly, patients on diuretics, patients with peripheral vascular disease and history of osteoporosis, and patients with reduced renal function [25,35]. Hence, the patient's age, fragility score, renal status, and other co-morbidities should be considered before prescribing these drugs.…”

Section: Discussionmentioning

confidence: 99%

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus

Rehman

Rahman

2020

Cureus

View full text Add to dashboard Cite

Cardiovascular (CV) diseases are the leading cause of mortality and morbidity in patients with type 2 diabetes mellitus (DM). Therefore, there has been an increasing endorsement from diabetic associations across the globe for the use of anti-diabetic drugs, which not only provide not only glycemic control but also have cardioprotective effects. Sodium-glucose co-transporter type 2 (SGLT2) inhibitors are one class of drugs that have shown evidence of CV benefits in patients with type 2 DM. We reviewed the published literature and found five adequately powered clinical trials that evaluated the CV effects of SGLT2 inhibitors in type 2 DM patients. These trials assessed the CV effect of three SGLT2 inhibitors, namely, empagliflozin, canagliflozin, and dapagliflozin. It was found that all these clinical trials were multi-centric and conducted in and after 2015 across different parts of the World, enrolling type 2 DM patients with varied baseline characteristics in terms of age, BMI, sex, glomerular filtration rate, history of existing renal diseases, etc. In spite of these differences, the SGLT2 drugs were found to be beneficial by significantly reducing all-cause mortality, mortality due to CV causes, and risk of major CV events. All the studies highlighted the cardioprotective effect of SGLT-2 inhibitors, especially empagliflozin, dapagliflozin, and canagliflozin in type 2 DM patients with established CV disease, but the studies could not find significant improvement in 3P-MACE

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus

Rehman

Rahman

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…We do not know what proportion this represents among the total number of SGLT2 treated patients across these 142 physicians. The incidence of mycotic infections in SGLT2 treated patients in clinical trials is 4-6% (Chaplin, 2016). In our study, more than half of the mycotic infections (59%) were treated without discontinuing the SGLT2 inhibitor.…”

Section: Discussionmentioning

confidence: 53%

“…These usually occur within the first four months of SGLT2 inhibitor treatment but first episodes can occur up to a year into treatment (Johnsson et al, 2013). Certain risk factors for mycotic infections have been identified, which include female sex, being an uncircumcised male and previous history of mycotic infection (Chaplin, 2016).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects

Patakfalvi

Brazeau

Dasgupta

2018

Prim Health Care Res Dev

View full text Add to dashboard Cite

We conducted a cross-sectional survey of all in-practice physicians (excluding pediatricians). Data were collected through an online survey.FindingsOur survey identified 154 physicians who have identified one or more adverse drug reactions (ADRs) related to SGLT2 inhibitor use. A total of 173 ADRs were identified. In total, 20.6% of family physician respondents had witnessed one or more ADRs. The most common complication is mycotic infection (82 cases) with 47% identified as a low level of severity and occurring mostly in the outpatient setting. The second most common complication is diabetic ketoacidosis (43 cases) with 67% identified as a high level of severity and occurring mostly in the inpatient setting. Other identified complications include hyperkalemia (6 cases), renal insufficiency (15 cases), and even amputation (2 cases). Our survey is the first to document real-world complications from SGLT2 inhibitors. In the outpatient setting, mycotic infections are most common and most often benign. In the inpatient setting, diabetic ketoacidosis is the most common and is severe. This is an important take-home message for family physicians to tailor their practice and vigilance according to the practice setting.

show abstract

“…Again, 0, 5, 10, 15, 20, and 25 mmol/L glucose solutions were quantified (together with 25 mmol/L of K 3 [Fe(CN) 6 ]). These quantities were chosen on the basis of the following facts: during the SGLT2 inhibitor therapy, daily glucose losses are usually between 70-120 g [28], and urinary glucose concentrations vary from 5 mmol/L (100 mg/dl) to 17 mmol/L (300 mg/dl) approximately after 6 hours of SGLT2-inhibitor ingestion [29].…”

Section: B Glucose Quantificationmentioning

confidence: 99%

Liquid-Core Microstructured Polymer Optical Fiber as Fiber-Enhanced Raman Spectroscopy Probe for Glucose Sensing

Azkune

Arrospide

Aldabaldetreku

et al. 2019

J. Lightwave Technol.

View full text Add to dashboard Cite

This work reports the development and application of two liquid-core microstructured polymer optical fibers (LC-mPOF) with different microstructure sizes. They are used in a fiber-enhanced Raman spectroscopy sensing platform, with the aim of detecting glucose in aqueous solutions in the clinically relevant range for sodium-glucose cotransporter 2 inhibitor therapy. The sensing platform is tested for low-concentration glucose solutions using each LC-mPOF. Results confirm that a significant enhancement of the Raman signal is achieved in comparison to conventional Raman spectroscopy. Additional measurements are carried out to obtain the valid measurement range, the resolution, and the limit of detection, showing that the LC-mPOF with 66-µm-diameter central hollow core has the highest potential for future clinical applications. Finally, preliminary tests successfully demonstrate glucose identification in urine. Index Terms-Fiber enhanced Raman spectroscopy, glucose sensing, hollow-core microstructured polymer optical fibers. I. INTRODUCTION A CCORDING to the World Health Organization, approximately 150 million people are suffering from diabetes mellitus worldwide. It is estimated that this number may well Manuscript

show abstract

SGLT2 inhibitors and risk of genitourinary infections

Cited by 17 publications

References 14 publications

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus

Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects

Liquid-Core Microstructured Polymer Optical Fiber as Fiber-Enhanced Raman Spectroscopy Probe for Glucose Sensing

Contact Info

Product

Resources

About